HAE:NYE-Haemonetics Corporation (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 96.49

Change

-0.88 (-0.90)%

Market Cap

USD 2.01B

Volume

0.27M

Analyst Target

USD 114.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Haemonetics Corp is a health care company.It provides products to customers involved in the processing,handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes & reduce costs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+5.19 (+2.29%)

USD 65.54B
ALC Alcon AG

+0.78 (+0.88%)

USD 43.58B
HYB New America High Income Closed..

+0.03 (+0.42%)

USD 35.93B
RMD ResMed Inc

-3.01 (-1.44%)

USD 32.13B
WST West Pharmaceutical Services I..

+2.29 (+0.70%)

USD 24.28B
BAX Baxter International Inc

+0.66 (+1.97%)

USD 17.04B
TFX Teleflex Incorporated

+2.43 (+1.18%)

USD 10.04B
ATR AptarGroup Inc

+1.55 (+1.06%)

USD 9.68B
STVN Stevanato Group SpA

+0.75 (+3.83%)

USD 5.45B
BLCO Bausch + Lomb Corp

-0.05 (-0.32%)

USD 5.41B

ETFs Containing HAE

RWM ProShares Short Russell20.. 0.00 % 0.95 %

-0.15 (-2.23%)

USD 0.17B
SRTY ProShares UltraPro Short .. 0.00 % 0.95 %

-0.61 (-2.23%)

USD 0.11B
TWM ProShares UltraShort Russ.. 0.00 % 0.95 %

-0.18 (-2.23%)

USD 0.07B
TZA Direxion Daily Small Cap .. 0.00 % 0.95 %

-0.41 (-2.23%)

USD 0.58B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.84% 74% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.84% 74% C 77% C+
Trailing 12 Months  
Capital Gain 12.80% 80% B- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.80% 75% C 48% F
Trailing 5 Years  
Capital Gain -3.58% 38% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.58% 31% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -1.69% 26% F 32% F
Dividend Return -1.69% 21% F 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.71% 53% F 33% F
Risk Adjusted Return -5.18% 21% F 23% F
Market Capitalization 2.01B 50% F 75% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.70 53% 17%
Price/Book Ratio 4.59 50% 20%
Price / Cash Flow Ratio 17.71 50% 20%
Price/Free Cash Flow Ratio 18.98 42% 15%
Management Effectiveness  
Return on Equity 14.72% 83% 72%
Return on Invested Capital 8.37% 68% 59%
Return on Assets 6.12% 68% 79%
Debt to Equity Ratio 92.19% 13% 39%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.